Trainee (Pharmacokinetic studies of biosimilars in trial registries: retrieval and evaluation)
Selection procedure reference: EMA/TR/11369
Deadline for applications: 06 May 2026 23:59 CET
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in Amsterdam. It began operating in 1995. It is responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
This traineeship opportunity is now open for applications until 06 May 2026 23:59 CET, with an intake on 1 October 2026.
About the traineeship programme
The Agency is looking for motivated, qualified recent graduates or students on an Erasmus+ or other programme or PhD students or Master's students (who posses a previous degree), who are interested in gaining experience and contribute to the Agency’s work for every patient in Europe. The purpose of a traineeship at the Agency is to perform tasks that are predominantly in the interest of the trainee’s training and principally serve to increase the trainee’s knowledge and to gain relevant experience.
Placement description
We are looking for a trainee in the Scientific Advice Office.
Specific objectives and projects
The successful candidate will conduct research, under the supervision and guidance of experienced colleagues, through public clinical trial registries and internal EMA regulatory resources on the development of biosimilar medicines, leading to a publication. Biosimilars have been introduced to lower the price of original biologics. However, hardly any independent research is published on how biosimilars are developed. One of the most contentious issues in the regulation of biosimilars is the link between structural and functional characteristics of the pharmaceutically active protein on the one side, and clinical efficacy and safety of the authorised biosimilar medical product on the other side. In their decision-making, regulators mostly rely on information from biosimilar developments that have reached a marketing authorisation application (MAA) stage. The goal of the research is to identify comparative biosimilar pharmacokinetic (PK) studies in a comprehensive manner, understand what portion of these studies meet their primary PK endpoints, what portion have reached an MAA stage in the EU and how information on the quality attributes, that underpin regulatory decisions to start the PK comparability study, can be retrieved from the registry records. The trainee will develop the core data sheet using multiple methodologies including supervised machine learning, contribute to interpretation of the results, and is expected to become one of the authors on a peer-reviewed publication.
Learning outcomes
Eligibility criteria
To be eligible for consideration for this placement, you are required to:
- enjoy full rights as a citizen of a European Union Member State or Iceland, Lichtenstein and Norway;
- possess a university degree in clinical pharmacology, biomedical sciences, or any other life sciences (minimum of three years or more) that must have been obtained between 6 May 2025 and 6 May 2026 or be a university student on an Erasmus + or a similar programme or a PhD student or a Master's student with a previous fully finished degree in the areas mentioned before.
- a thorough knowledge of English (at least level C1) and good knowledge of other official EU language (at least B2) of the Common European Framework for Languages
For criteria 1 and 2, you will be required to provide proof in the application form and at the interview stage. Failing to present these documents may result in the disqualification from the procedure.
Additional skills
Strong analytical skills; diligent and systematic approach to work; high attention to detail; and a solid understanding of scientific methodology.
Behavioural Competencies
You will demonstrate the following behavioural competencies:
- Communication skills
- Interpersonal skills
- Working with others
- Adaptability
- Research and analytical skills
- Learning and development
Conditions of traineeship
The traineeship is offered for 10 months (1 October 2026 – 31 July 2027) and takes place at the Agency’s premises in Amsterdam with possibility for teleworking up to 40% of working time from The Netherlands and occasional teleworking from outside The Netherlands. Traineeships are offered for either full-time or part-time (80% or 50%) if combined with university studies.
The Agency pays a monthly stipend of €2,049.77 for a full-time traineeship (reduced accordingly for 80% or 50%) and a travel contribution upon joining the Agency.
Each trainee will have a mentor at the Agency who will guide the trainee through the programme.
The conditions of employment are stated in the Executive Decision on rules governing the traineeship programme at the EMA available here.
Expected selection timelines
| Deadline for applications | 06 May 2026 23:59 CET |
|---|---|
| Assessments (remote) | From mid-June 2026 to mid-July 2026 |
| Decision and offers | By end of July 2026 |
| Placement start | 1 October 2026 |
______________________________________________________________________________________________________
Domenico Scarlattilaan 6 - 1083 HS Amsterdam - The Netherlands
Telephone +31 (0)88 781 6000 - Email recruitment@ema.europa.eu
© European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged.
Job Segment:
Law, Trainee, Network, Research, Legal, Entry Level, Technology